Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital.
Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital.
复制标题
DOI：
10.5581/1516-8484.20130053
复制
发表时间：
2013
影响因子：
--
通讯作者：
de Oliveira MF
中科院分区：
文献类型：
--
作者：
Dos Reis SR;Quixadá AT;Nunes ST;Cid DM;de Souza JH;da Costa CM;Silveira CB;Cid DA;de Oliveira MF
本研究的目的是确定慢性粒细胞白血病患者坚持甲磺酸伊马替尼治疗失败的原因。 对100例接受甲磺酸伊马替尼治疗的Ph+慢性粒细胞白血病患者的非电子记录进行了回顾性分析。研究时间为2001年1月至2011年1月。使用统计分析系统软件包通过卡方和对应分析来分析数据。 在治疗开始时，41%的患者处于疾病的晚期。药物不可用（44.8%）和骨髓毒性（25.7%）是最常见的中断原因。47%的病例依从率< 90%。低粘附性影响细胞遗传学缓解（p值= 0.020）和分子学缓解（p值= 0.001）。非常高的依从性（> 95%）诱导了完全细胞遗传学缓解、主要细胞遗传学缓解和主要分子学缓解。 与其他研究相比，本研究人群获得的治疗反应低于预期。
The aim of this study was to identify the reasons for failure in adherence to imatinib mesylate treatment in chronic myeloid leukemia. A retrospective review was performed of 100 non-electronic records of patients with Ph+ chronic myeloid leukemia treated with imatinib mesylate. The study period was from January 2001 to January2011. Data were analyzed by Chi-Square and Correspondence analysis using the Statistical Analysis System software package. At the beginning of treatment 41% of patients were in advanced stages of the disease. The unavailability of the drug (44.8%) and myelotoxicity (25.7%) were the most frequent reasons for interruption. The adherence rate was < 90% in 47% of the cases. The low adherence influenced the cytogenetic response (p-value = 0.020) and molecular response (p-value = 0.001). Very high adherence (> 95%) induced complete cytogenetic response, major cytogenetic response and major molecular response. The population of this study obtained lower-than-expected therapeutic responses compared to other studies.